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The prevalence, characteristics and morbidity of neuropathic pain in AIDS patients, prior to 
the use of HAART, at the Kalafong Hospital HIV clinic, Pretoria. 
Introduction: 
Neuropathic pain, of which a distal sensory polyneuropathy (DSP) is the most frequent 
cause, is a common problem in patients with HIV infection and AIDS. 
The researcher is concerned that neuropathic pain in patients with AIDS tends to be under-
diagnosed and under-treated. There are several reasons for this, one of which may be a lack 
of awareness of the extent of the problem, as well as the impact it has on patients' lives. 
Several studies around the world have noted the problem of under-diagnosis and under-
treatment of pain and more specifically, neuropathic pain, in patients with AIDS. 
A review of the literature reveals a wide variation in the prevalence of neuropathic pain and 
peripheral neuropathy in AIDS patients. 
Aim: 
To determine the prevalence, characteristics, severity and morbidity of neuropathic pain in 
AIDS patients, attending the Kalafong HIV Clinic, prior to the initiation of HAART. 
Methods: 
A prospective, cross sectional and descriptive study was done at the Kalafong Hospital HIV 
Clinic. Data was collected from a systematic sample of 354 AIDS patients, who were referred 
to this HIV clinic to be initiated on HAART. 
An interviewer-administered questionnaire and focused neurological examination were used. 
This included a recently validated instrument, the DN4, for identifying pain which is 
neuropathic in origin. Selected sections of the Brief Pain Inventory (BPI) were used to 
determine the severity of the neuropathic pain, as well as pain-related interference on 












Twenty one percent (95% CI: 16.8% to 25.2%) of AIDS patients had pain of predominantly 
neuropathic origin (POPNO). This pain was significantly more frequent in patients who were 
male, had lower CD4 cell counts or higher viral load levels and those with a history of recent 
or current use of treatment for tuberculosis. The majority of patients (79.7%) with POPNO 
experienced substantial pain (worst pain severity ~ 5 out of 10 on a numerical rating scale). 
Pain-related interference with aspects of daily living was highest for enjoyment of life, mood 
and the ability of these patients to work. Abnormalities of tactile and pinprick sensation and 
vibration sense were the commonest neurological findings in patients identified as having 
POPNO. 
Conclusion: 
Pain of predominantly neuropathic ongm results in substantial suffering and impaired 
functioning in patients with AIDS. It is therefore imperative that clinicians should carefully 
assess patients with AIDS for the presence and seventy of neuropathic pain and treat it, 
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Infection with the Human Immunodeficiency Virus, together with a history of a AIDS-defining 
condition or a CD4 lymphocyte count of less than 200 cell/mm3 (based on the 1993 Centers 
for Disease Control case definition criteria for AIDS) (CDC, 1993). 
CD4 cell count: 
The concentration, in the blood, of T lymphocytes, that express the CD4 receptor. This 
measurement is expressed as cells/lJl or cells/mm3 . 
HIV Viral load: 
The concentration, in the blood, of free virus, identified by measuring HIV1 RNA. The 
measurement is expressed as viral copies/ml. 
National Department of Health HIV Antiretroviral Programme: 
The public health sector programme in South Africa, whereby several regimens of HAART 
(Highly Active Antiretroviral Therapy) is made available to all patients, who are dependent on 













As a family physician with a special interest in palliative medicine, the researcher has 
encountered many patients with HIV (Human Immunodeficiency Virus) infection, with 
troublesome neuropathic pain. These patients were seen both at the Kalafong Hospital, as 
well as in the hospice situated nearby the hospital. The Kalafong Hospital is an 850-bed 
regional state hospital in Pretoria (Tshwane). According to the National Health policy, HIV 
infected patients who do not yet require ARV (antiretroviral) therapy and who are clinically 
stable, are managed by a general practitioner or primary health care clinic. Patients 
dependent on the public health system, requiring ARV therapy, are referred to the HIV clinic 
of the Kalafong Hospital. The Leratong Hospice is an 18 bed unit situated 8 km from the 
Kalafong Hospital. The majority of admissions to this hospice have advanced AIDS (Acquired 
Immune Deficiency Syndrome) and require supportive care, symptom control or terminal 
care. With the increasing availability of ARV therapy in the public health sector, many of 
these patients require disease-specific curative management, rather than terminal care. 
There is a close working relationship between this hospice and the clinicians at the Kalafong 
Hospital. 
The human immunodeficiency virus has a predilection for nerve tissue. Therefore the 
peripheral nerves, the spinal cord and the brain are frequently affected in HIV/AIDS, resulting 
in a high incidence of neuropathic pain (Belgrade, 1999). It is thought that up to 40% of pain 
in patients with HIV is due to neuropathic pain syndromes (Stephenson, 1996). 
Neuropathic pain is currently defined by the International Association for the Study of Pain 
(IASP) as "pain initiated or caused by a primary lesion or dysfunction of the nervous system" 
(IASP, 1994). The lesion may be within the central nervous system, at the level of the dorsal 
root ganglion, or a peripheral nerve. This injury may lead to structural and functional changes 
in the nervous system, resulting in altered peripheral and central neural processing of 
sensory input (central sensitisation) (Dworkin et ai, 2003 & Galer et ai, 1997). Consequently, 
pain may persist long after healing of the original injury (Brunton, 2004). Pain, other than 
neuropathic pain, is elicited by the activation of unmyelinated C fibres and thinly myelinated 
AtJ fibres. When there is no noxious stimulus, these afferent fibres are silent (Holdcroft et ai, 
2005). In the situation of injury to the nervous system, however, spontaneous afferent activity 
may occur, resulting in neuropathic pain (Holdcroft et ai, 2005). 
Neuropathic pain syndromes typically present with both negative and positive sensory 
symptoms and signs, (Dworkin et ai, 2003 & Backonja et ai, 1998) in the anatomical area 











of neuropathic pain are burning, pricking, shooting or aching (Holdcroft, 2005). This may be 
accompanied by hyperalgesia (increased pain in response to a noxious stimulus), allodynia 
(elicitation of pain in response to a non-noxious stimulus), dysesthesia (abnormal unpleasant 
sensation) or paresthesia (abnormal sensation which is not unpleasant). Negative sensory 
symptoms such as numbness are common. After-sensation (pain continuing after the 
stimulation has ceased), referred pain (pain felt in a place apart from the stimulated area) 
and wind-up pain (abnormal temporal summation of pain), may also occur in the situation of 
neuropathic pain (Holdcroft, 2005). Pain may be spontaneous or evoked. Evoked pain could 
result from stimuli such as pressure of clothing or cold temperatures. (Dworkin et ai, 2003). 
Motor symptoms and signs occur less commonly. These too, can be viewed as negative or 
positive. Negative signs include hypotonia, decreased muscle strength and decreased 
endurance. Positive signs are increased muscle tone, tremor, dystonia or incoordination 
(Backonja et ai, 1998). 
Neuropathic pain can be divided into three broad categories namely; peripheral 
mononeuropathy (e.g . trigeminal neuralgia, nerve compression by a tumour or post-herpetic 
neuralgia), peripheral polyneuropathy (e.g. diabetic, alcoholic and HIV neuropathy) and 
central neuropathy (e.g. post-stroke syndrome and HIV myelopathy) (Dworkin et ai, 2003 & 
Brunton, 2004). 
The clinical differentiation between nociceptive pain and neuropathic pain is not always clear-
cut, because there is considerable overlap in patients' descriptions of their pain symptoms. 
Furthermore, the clinical diagnosis of neuropathic pain is open to error because of the 
absence of a consistent, clear and testable definition of neuropathic pain (Bennett et ai, 2005 
& Bouhassira et ai, 2005). It has been suggested that neuropathic pain is not necessarily a 
dichotomous phenomenon of "it is", or "it is not" but may be part of a spectrum where the 
pain is "more or less neuropathic" in origin (Smith et ai, 2007; Torrance et ai, 2006; Attal et 
ai, 2004). This gave rise to the concept of pain of predominantly neuropathic origin (POPNO) 
(Torrance, 2006). 
No single symptom or sign is pathognomonic of neuropathic pain . The European Federation 
of Neurological Societies' guidelines on neuropathic pain assessment, emphasises the 
importance of a thorough neurological examination, especially the sensory aspects thereof 
(Cruccu et ai, 2004). At the same time, the absence of neurological signs does not rule out 
the presence of neuropathic pain (Backonja et ai, 1998). The finding of both negative and 
positive sensory symptoms or signs in the same anatomical area of pain, is a strong 
predictor of neuropathic pain (Dworkin et ai, 2003). The anatomical distribution of neuropathic 











of a spinal cord level (Belgrade, 1999). Unlike most other pains, neuropathic pain is often 
worst at night (Belgrade, 1999). 
The often-confusing set of symptoms and signs associated with neuropathic pain, 
necessitate patients to be instructed, before the examination, to carefully describe exactly 
what they feel. Any stimulus should be applied first to an unaffected area and then to the 
painful area. Patients need to respond whether the stimulus in the painful area is the same, 
less or worse than the unaffected area (Dworkin et ai, 2003) . 
There is no single diagnostic special investigation which will identify pain as being 
neuropathic. Abnormal nerve conduction studies occur in approximately 81 % of patients with 
a distal sensory polyneuropathy (DSP), whilst the remaining 19% show no abnormality 
(Tagliati et ai , 1999). Since conventional nerve conduction studies are not able to assess the 
function of the small myelinated and unmyelinated fibres involved in pain and temperature 
sensation, there is frequently no relationship between painful symptoms and 
electrophysiological alterations (Dworkin et ai, 2003 & Bouhassira et ai, 1999). 
The commonest cause of neuropathic pain in patients with HIV infection is a peripheral 
neuropathy (Stephenson, 1996). A variety of sensory neuropathies may occur throughout the 
course of HIV infection, including acute and chronic inflammatory demyelinating 
polyneuropathy, mononeuritis multiplex (sometimes associated with cytomegalovirus and 
varicella zoster virus) and progressive polyradiculopthy (Keswani et ai, 2002 & Brinley et ai, 
2001) . The most common and clinically important neuropathy is a distal sensory 
polyneuropathy (DSP) (Brinley et ai, 2001 & Watters et ai , 2004), which is thought to be due 
to neurotoxic substances of both HIV viral and monocyte/macrophage origin (Brinley et ai, 
2001 & Verma et ai, 2005). A toxic neuropathy from ARV drugs is an increasingly common 
cause of peripheral neuropathy in patients with HIV infection. The nucleoside reverse 
transcriptase inhibitors (NRTI's), such as didanosine, stavudine and zalcitabine are the worst 
offenders in this regard (Brinley et ai , 2001). This drug-induced neuropathy may produce 
such severe symptoms that patients are forced to use alternative ARV medication, which 
reduces future treatment options (Brinley et ai, 2001). The decision whether to change ARV 
medication is made difficult by the fact that HIV-associated DSP and antiretroviral toxic 
neuropathy are clinically indistinguishable and many patients have contributions from both 
causes (Verma et ai , 2005 & Simpson et ai, 2003). NRTI-induced neuropathies tend to be 
reversible, although symptoms may continue to worsen for a while, even after discontinuation 
of the drug (Brinley et ai , 2001; Verma et ai, 2005; Berger et ai, 1993). In South Africa, where 
tuberculosis and HIV infection frequently occur concurrently, the anti-tuberculous drug, 











Neuropathic pain in HIV-infected patients may also be due to malignancies, which occur with 
increased frequency in HIV-infected patients. These sometimes infiltrate nerves resulting in 
neuropathic- or mixed neuropathic and nociceptive pain. There is some evidence that the 
incidence of cerebrovascular incidents is increased in patients with HIV infection (Cole et ai, 
2004) . These may give rise to neuropathic pain of central origin . Herpes zoster in 
immunodeficient patients tends to be multidermatomal and recurrent (Wilson et ai, 2002). 
This and its complication of post herpetic neuralgia is an additional cause of neuropathic 
pain , in this group. 
In patients with a symptomatic neuropathy, pain occurs predominantly in the lower limbs, 
especially in the toes and soles of the feet. Painful symptoms include burning or deep pain, 
intense pins and needles, hyperesthesia (with sensitivity to contact e.g. with socks or bed 
sheets), paroxysmal shooting pains or combinations of these. Numbness may also be 
present (Bouhassira et ai, 1999 & Verma et ai, 2005). Patients with DSP may alter their gait 
to avoid painful pressure on their feet and they may have disturbed sleep. Symptoms may be 
severe and may significantly impair a patient's quality of life and functional ability (Verma et 
ai, 2005 & Simpson et al. 2003). 
Treatment of painful peripheral neuropathy in HIV infection is difficult. No treatment is known 
to reverse its course (Keswani et ai, 2002 & Simpson et ai, 2003), therefore treatment is 
aimed at improving symptoms. Consistent and prolonged suppression of viral load using 
HAART results in a decline of the development of DSP (Brinley et ai, 2001) . Any neurotoxic 
drugs that the patient may be using, should be discontinued. Several drugs may result in a 
significant degree of relief for neuropathic pain in general. These results have been 
confirmed in published double-blind, placebo-controlled, randomised studies. First-line 
agents include certain antidepressants (i.e. tricyclic antidepressants [TCA's] and dual 
reuptake inhibitors of both serotonin and norepinephrine [SNRI'sD, the anticonvulsant, 
gabapentin and in selected circumstances, opioid analgesics (Dworkin et ai, 2007). Certain of 
these agents have been tested in trials specifically looking at efficacy in HIV sensory 
neuropathies. The results have been less promiSing than for neuropathies of other 
aetiologies. The only therapies shown to offer symptomatic treatment of HIV neuropathies, in 
randomized placebo-controlled studies, are lamotrigine and recombinant human nerve 
growth factor (Keswani et ai, 2002 & Simpson et aI, 2003). 
Although neuropathic pain in AIDS patients is common and results in significant patient 
suffering and functional impairment, it is frequently under-diagnosed and under-treated. A 
study in the USA found that 63% of patients with symptomatic peripheral neuropathy had not 
been diagnosed by their clinicians prior to the study (Estanislao, 2003). Stephenson, 1996 











inadequate diagnosis of neuropathic pain in AIDS patients. However, both Stephenson, 1996 
and Larue et ai, 1997 found that even when HIV-related pain is recognised, the majority of 
patients with significant pain do not receive any or adequate analgesic treatment. Larue et 
ai, 1997 found that inadequate assessment of pain and under-estimation of its severity and 
its impact on patients' quality of life, may result in poor management of pain. Furthermore, 
failure to recognize when neuropathic pain mechanisms predominate, results in failure to 
treat patients with the most appropriate drug regimens, which include adjuvant medication 
such as certain antidepressants and anticonvulsants. In a study of pain in HIV patients, 
Breitbart et ai, 1996b found that only 10% of patients were prescribed an adjuvant drug, 
despite the fact that almost 50% of the pain was related to neuropathic pain syndromes. 
The present study aimed to identify the prevalence, severity and impact of pain that is 
predominantly neuropathic in origin, in patients with AIDS, prior to the initiation of HAART 
(highly active antiretroviral treatment). It is hoped that greater awareness of the extent of the 
problem may prompt clinicians to perform a more thorough evaluation of their patients' pain, 
leading to a more specific diagnosis and appropriate prescribing of analgesia and adjuvant 
medication. 
In addition, since this study focused on neuropathic pain in pre-HAART subjects, the findings 
of this study could be used as a baseline from which to assess the influence of HAART, on 
the prevalence of neuropathic pain in patients with AIDS. 
A further objective of the study was the identification of the most frequent symptoms and 
signs found with neuropathic pain, which can be used by clinicians in the discrimination 













Literature search and Key words: 
A literature search was done using the MEDLINE database. Google Scholar was used to 
extend the search and an expert in the field assisted with literature that he considered 
important. The following key words were used: neuropathic pain. peripheral neuropathy. 
polyneuropathy. HIV. AIDS. pain assessment. pain interference. 
Neuropathic pain in HIV/AIDS 
Pain is a significant problem in patients with HIV infection and AIDS. comparable to that 
experienced by cancer patients (Lebovits et al. 1989). In a study of ambulatory AIDS patients 
in the USA. Breitbart et al.1996a found that 62% reported frequent or persistent pain during 
the past two weeks. One or more pains were reported by 80% of AIDS subjects. in a Los 
Angeles study of male patients by Singer et al. 1993. Norval. 2004 studied AIDS patients 
registered with the Soweto Hospice Association Programme in South Africa and found pain 
to be the most prevalent symptom amongst the sample. with 98% experiencing pain. This 
particularly high incidence in the Norval study may be due to the fact that hospice patients 
are likely to have advanced disease. 
Only limited evidence could be found in the scientific literature. regarding the prevalence of 
neuropathic pain in general, in AIDS patients. In a study of ambulatory AIDS patients in New 
York. Breitbart et ai, 1996a found 46% of a subset of patients with pain had one or more 
neuropathic pains. 1\10 study could be found that had determined the prevalence of 
neuropathic pain in general in AIDS patients. within the entire sample. Numerous studies 
have examined the prevalence of distal sensory polyneuropathy (aSP) in HIV infected 
patients. Many of these studies included both symptomatic and asymptomatic neuropathy. 
Only those studies reporting on symptomatic peripheral neuropathy are discussed. In a USA 
study. Schifitto et al. 2002 found that 35% of pre-HAART AIDS patients met the criteria for a 
symptomatic DSP. while 37% of HIV-infected subjects in a Hawaii study of Watters et al. 
2004. had a symptomatic DSP. In this study. symptomatic DSP occurred significantly more 
frequently in patients older than 50 years. as compared to the younger patients. A small 
study of hospitalized AIDS patients in San Francisco by So et ai, 1988. found a DSP 
prevalence of 35%. A study in Los Angeles by Singer et al. 1993. found that peripheral 
neuropathy was responsible for the pain in 59% of AIDS patients with pain. Another aspect 
of neuropathic pain was examined by a New Jersey dental school. In this study, Fischoff et 











pain. Studies from the African continent, focusing on neuropathic pain in HIV-infected 
patients, indicate widely variable prevalence rates of peripheral neuropathy. In a recent study 
in Uganda, Nakasulla et ai, 2005 found the prevalence of peripheral neuropathy in HIV-
infected patients at different stages to be 44%, of whom just over half were asymptomatic. 
This would produce a prevalence of symptomatic peripheral neuropathy in HIV patients, of 
approximately 20%. A much higher prevalence of symptomatic peripheral neuropathy was 
found in a study by Mbuya et ai, 1996, of AIDS patients admitted to a Kenyan hospital. Here, 
45% of patients had symptoms of a peripheral neuropathy. The commonest symptom was a 
dysesthesia and the commonest sign was a loss of vibration sense. nlis high prevalence 
may relate to the fact that hospitalized patients tend to have more advanced disease or other 
complications of HIV infection. No neuropathic pain prevalence study originating from South 
Africa was identified. 
A number of studies examined risk factors for the development of DSP in patients with HIV 
infection. Tagliati et ai, 1999, demonstrated that a lower CD4 cell count, older age, male 
gender and Caucasian race were associated with a higher incidence of DSP. Morgello et ai, 
2004 also found a definite significant correlation between DSP and older age and male 
gender. In this study, initial statistical analysis also found patients with DSP to have lower 
CD4 cell counts, however, no association between DSP and plasma viral load was indicated. 
The severity of the pain in HIV-associated peripheral neuropathy was shown by Simpson et 
ai, 2000, to be significantly worse in patients with a higher HIV viral load. Other sources 
indicate a lower CD4 cell count and advanced disease to be associated with a greater risk of 
HIV-infected patients developing DSP (Brinley et ai, 2001 & Verma et ai, 2005). Naturally, 
concurrent causes of neuropathy, such as diabetes mellitus, alcoholism and deficiencies of 
vitamin B12 and thiamine, may increase the risk of developing DSP (Brinley et ai, 2001). 
Assessment of pain and neuropathic pain 
The definition of pain, according to the International Association for the Study of Pain (IASP), 
is "an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage" (IASP, 1994). Pain is a subjective 
experience. What a patient communicates about his pain, verbally or non-verbally, is 
therefore an important aspect of the measurement of that pain (Ong et ai, 2004). A patient's 
self report, may provide the most valid measure of the experience of pain and is considered 
the gold standard of pain measurement (Brunton, 2004 & Turk et ai, 1992). 
A pain measurement test needs to be reliable (giving the same test scores when measuring 











which it is supposed to measure) and sensitive (as far as possible covering the whole 
dimension of what it is intended to measure) (Ong et ai, 2004). 
The requirements of this study were first to identify the number of patients in the sample, who 
had POPNO and then to quantify this pain experience and its impact on the patient's 
functioning. Several instruments have been developed with the purpose of identifying 
neuropathic pain or POPNO. These include the Leeds Assessment of Neuropathic 
Symptoms and Signs Scale (LANSS), the Neuropathic Pain Questionnaire (NPQ) and more 
recently, the Neuropathic Pain Diagnostic Questionnaire (DN4) . 
The LANSS was developed at the Chronic Pain Management Service at St James University 
Hospital in Leeds (Bennet, 2001). It is a simple and valid 7 -item tool, using a binary response 
(yes or no) to the presence of five symptoms (sensory description) and two clinical signs 
(examination of sensory dysfunction) (Bennet, 2001 & Bennet et ai, 2005) . When used to 
differentiate neuropathic from non-neuropathic pain, the LANSS has a sensitivity of 83% and 
specificity of 87% (Krause et ai, 2003). One difficulty with using the LANSS Pain Scale, 
relates to the symptom of skin colour change. This was likely to pose a problem in this 
study's population, where many of the patients are dark-skinned. 
The NPQ was developed to function as a diagnostic and measurement tool. The intensity of 
12 neuropathic symptoms is assessed and discriminate function coefficients are used to 
calculate the total score. No examination is included in this tool (Bennet et ai, 2005 & Krause 
et ai, 2003). 
The French Neuropathic Pain Group recently developed a 10-item clinician-administered 
questionnaire named the Neuropathic Pain Diagnostic Questionnaire (DN4) (Bouhassira et 
ai, 2005 & Jensen, 2005). As with the LANSS Pain Scale, it measures the presence of a 
number of sensory symptoms and signs. This includes 7 pain qualities and three examination 
items (hypoesthesia to touch and pinprick and allodynia). Each positive item is given a score 
of 1 and negative items are scored as O. The cut-off value for the diagnosis of neuropathic 
pain is 4/10. This tool was validated in a single study and was found to have a sensitivity of 
82.9% and specificity of 89.9% for identifying neuropathic pain (Bouhassira et ai, 2005 & 
Jensen, 2005). The relatively small number of items to be measured and the simplicity of the 
scoring method of the DN4 made this instrument an appropriate option for this study, which 
was likely to include several ill or debilitated patients. The DN4 could potentially be a useful 
tool in palliative medicine research and clinical practice. It should be noted that none of these 
scales have yet been widely used, nor used in HIV/AIDS populations and have therefore only 











Other measurement tools for neuropathic pain are the Neuropathic Pain Scale (NPS) and the 
Neuropathic Symptom Inventory (NPSI). While both these tests discriminate between 
different categories of neuropathic pain and their scores have been shown to change in 
response to treatment of the pain. they were not developed to discriminate neuropathic pain 
from non-neuropathic pain (Galer et al. 1997; Bennet et al. 2005; Krause. 2003). Cherry et al. 
2005 evaluated The Brief Neuropathy Screening Tool and found it to be a valid screening 
tool for detecting HIV-associated sensory neuropathies. It was. however. used to detect 
peripheral nerve dysfunction. rather than a symptomatic neuropathy and was therefore not 
considered appropriate for this study. 
Several instruments are available for the measurement of a patient's pain experience. 
Unidimensional scales. such as the numerical rating scale (NRS) or visual analogue scale 
(VAS). are used to determine a score of a patient's pain intensity. The validity of these scales 
has been well documented and they are simple for patients to understand and easy to use. 
While a NRS could be used to measure the severity of pain in this study. this unidimensional 
scale would only measure pain intenSity and a multidimensional pain scale was indicated to 
measure functional and emotional dimensions of the pain. 
Examples of multidimensional pain scales are the McGill Pain Questionnaire (MPQ) and the 
Brief Pain Inventory (BPI). The MPQ attempts to assess the three dimensions of the pain 
experience. namely the sensory. affective and evaluative components of pain. There is a 
checklist of 87 descriptors of the sensory qualities of a patient's pain and related emotions. 
The reliability and validity of this scale have been confirmed in many studies. It has been 
used to measure a variety of different kinds of pain. but not specifically neuropathic pain. Its 
disadvantage is that it is time-consuming and requires patients to possess a fairly 
sophisticated vocabulary (Ong et al. 2004). It was therefore not considered suitable for this 
study setting. where. for several patients. the study questions had to be translated into 
another language. The BPI is a widely used and validated instrument. which measures the 
severity of pain and its interference with daily functioning (Zelman et al. 2005 & Daut et al. 
1983). Its brevity and ease of use make it particularly useful in both clinical and research 
settings (Poundja et al. 2007). The BPI has been used in several different clinical settings. 
including patients with HIV disease (Poundja et al. 2007). A French study by Larue et al. 
1997 and a New York study by Breitbart et al. 1996b. on the undertreatment of pain in AIDS 
patients. used the BPI as a measure of pain. The BPI measures worst. least and average 
pain levels. during the last 24 hours. on an 11-point numerical rating scale. Pain location is 
recorded on a pain drawing. An NRS is also used to rate the degree to which pain interferes 
with multiple aspects of life. Some of these aspects include ability to work. walking ability. 












• Neuropathic pain is the result of injury to the peripheral or central nervous system. It 
has several aetiologies in patients with HIV and AIDS, the commonest being a type of 
peripheral neuropathy known as a distal sensory polyneuropathy. 
• There is more evidence relating to the prevalence of AIDS-related peripheral 
neuropathy than neuropathic pain in general. 
• The prevalence of peripheral neuropathy in patients with HIV and AIDS varies 
considerably in different studies around the world. 
• No study, that originated in South Africa, relating to the prevalence of neuropathic 
pain or peripheral neuropathy in AIDS patients, was found . 
• Assessment of neuropathic pain is difficult, due to both the lack of a clear clinical 
definition, as well as neurological guidelines for the diagnosis of neuropathic pain. 
The Neuropathic Pain Diagnostic Questionnaire (DN4) may provide a simple and 












AIM AND OB .. IECTIVES 
The aim of this study is to determine the prevalence, characteristics and morbidity of 
neuropathic pain in AIDS patients, who attended the Kalafong HIV Clinic, prior to the 
initiation of HAART. 
Primary Objectives 
• To identify what percentage of AIDS patients, attending the Kalafong HIV Clinic, have 
POPNO, prior to the initiation of HAART. 
• To identify the perceived intensity of pain in those patients with POPNO. 
• To assess the perceived impact of the POPNO on patients' physical and psycho-
social functioning. 
• To identify the most prevalent symptoms and signs of POPNO in AIDS patients. 
Secondary Objectives 
• To improve awareness amongst clinicians, regarding the extent and impact of 
neuropathic pain in AIDS patients. 
• To produce baseline data to be used in comparing the prevalence of POPNO in 














This is a prospective, cross sectional and descriptive-analytic study. 
Subjects and sampling 
The study population included all patients attending the Kalafong HIV Clinic for the first time. 
The majority of patients referred to this clinic, meet the requirements for the National 
Department of Health's HIV ARV programme. This means that they are patients with 
confirmed AIDS, either with a history of an AIDS-defining condition or a CD4 cell count of 
less than 200 cell/mm3 . 
All patients attending the Kalafong HIV clinic for the first time, are required to attend a 
preparation visit, during which they are counselled and informed regarding the use of ARV's. 
These preparation visits take place on the Monday and Thursday of each week. All the 
patients attending each of these preparation visits, were invited to participate in the study. 
Only those patients meeting the inclusion criteria were included in the sample. Sampling 
continued until the desired sample number was reached. 
To determine the sample size, the following approximate formula was used: 
where n = sample size 
p = proportion 
d = level of accuracy 
Note: Z ~ = 1.962 
The prevalence of pain in this study population was estimated as 50% and neuropathic pain 
as 5% - 10%. It was therefore expected that about 50% of subjects would be classified as 
being positive to the study variable. Using the mentioned formula, given different sample 
sizes (n) and using a 95% level of confidence, 























Therefore, with the sample of 354 subjects, an accuracy level of 5.2% should have been 
achieved. 
Study Procedure 
Lay counsellors do pre- and post-test HIV as well as ARV counselling at the Kalafong HIV 
clinic. Six of these counsellors were available as research assistants on their off-duty days. 
One research assistant was on duty each research day and he/she handed each of the 
patients attending the clinic for a preparation visit, the study information sheet (Appendix 1). 
In the times before or after the preparation sessions, the research assistant approached 
each patient individually and explained any parts of the study information sheet that were 
unclear. He/she then assisted those patients who were willing to participate in the study, to 
sign the informed consent form (Appendix 2). Both the information sheet and the informed 
consent form were available in English, Afrikaans, Tswana and Zulu. The research assistants 
were all competent in these same languages and almost all the patients attending this clinic 
are able to communicate in one of these languages. The research assistants were trained in 
issues of patient communication, research ethics (such as avoiding any influence or 
coercion) and confidentiality. 
Inclusion criteria: 
1. Patients with a confirmed diagnosis of AIDS i.e. HIV infection with either a history of 
an AIDS-defining condition or a CD4 cell count of less than 200 cell/mm3. 
2. Patients 18 years and older. 












1. Patients who were unable to understand or answer the questionnaire due to cognitive 
impairment or language difficulties, in spite of the availability of the translator. 
2. Patients with severe systemic illness, who may have experienced the additional 
questioning and examination as too burdensome. 
3. Patients attending the Kalafong HIV Clinic for the first time, but who were already 
using ARV agents, prescribed by another institution or clinician. 
Data collection method 
The research data was collected using an interviewer-administered paper questionnaire, 
which included a focused neurological examination (Appendix 3). In this questionnaire, the 
method used to identify the subsection of the sample who had pain in general, was adapted 
from a question used to identify patients with pain, in a large study of pain in ambulatory 
patients with AIDS in the USA (Breitbart et ai, 1996a & Hewitt et ai, 1997). In this USA study, 
patients were asked the question: "During the past two weeks, have you experienced 
persistent or frequent pain of any type?" The language of this question was adjusted to make 
it more meaningful for the present study's population. Several aspects of this questionnaire 
were based on the Brief Pain Inventory (BPI). Although the BPI is a valid and reliable 
measure of pain, the focus of this tudy was neuropathic pain and a further instrument was 
required to identify those patients with POPNO. For this purpose, the DN4 was chosen, from 
several clinical instruments used to measure neuropathic pain, due to the relative simplicity 
of its questions and examination items. This was considered to be important for this study in 
a palliative care setting, where many of the subjects may be feeling ill, weak or fatigued. The 
DN4 has been shown, in a single study, to be a valid tool for the identification of neuropathic 
pain (Bouhassira et ai, 2005 & Jensen, 2005). It has, however, not been subject to other 
validation studies, nor has it been used for studying HIV populations. 
Both the questions and the neurological examination, were administered by the researcher, 
with the help of a translator (one of the research assistants) where required. The researcher 
read the questions to the patients and recorded their responses. This method enhanced the 
quality of the data because the interviewer could clarify, but not amplify, the questions or 











Tools of measurement 
The questionnaire was divided into the following sections: 
• A demographic section which included age, gender and use of tuberculosis 
treatment. The CD4 cell count, on the referral note of the patient to the HIV Clinic, 
was recorded in this section of the questionnaire. On the day of the first visit to the 
HIV Clinic, the HIV viral load is measured in all patients who qualify to use ARV's. 
This result was obtained and recorded from the records of the ARV Clinic, once it 
was available. 
• The presence of pain was assessed by asking all patients the following question: 
"During the past two weeks, have you experienced any pain that has troubled you a 
lot?" Only the subsection of patients identified as having pain, continued with the 
questionnaire. 
• A body map for patients to indicate the location of their pain(s). 
• The Neuropathic Pain Diagnostic Questionnaire (DN4): 
Using this instrument, each patient was asked to answer "yes" or "no" to the following 
seven pain qualities or sensations in his/her area of pain: burning, painful cold, 
electric shocks, tingling, pins and needles, numbness and itching. This instrument 
included three examination items, to check for the presence of hypoesthesia to 
touch, hypoesthesia to pain and dynamic allodynia of the skin overlying the area of 
pain. The painful area was compared to an adjacent or contra lateral non-painful 
area of skin. Cotton wool was used for the modality of touch, a cocktail stick was 
used to elicit pinprick pain and brushing with cotton wool was used to elicit any 
allodynia. Each positive item was given a score of 1 and negative items were scored 
as O. The cut-off value for the diagnosis of pain of predominantly neuropathic origin 
(POPNO) was 4/10. 
Only patients, whose pain was identified as neuropathic in origin by using the DN4, 
were required to complete the remaining sections of the questionnaire. These 
included: 
• A focused neurological examination to identify any sensory or motor deficits in the 
area identified as having pain of predominantly neuropathic origin: 
The following sensory aspects were tested; tactile, pinprick, and vibration sense, 











and cold thermal allodynia. (Certain of these had already been measured during the 
application of the DN4). Dynamic allodynia was tested by brushing the skin with 
cotton wool, while static allodynia was tested by blunt pressure with a finger, at a 
pressure that does not evoke pain in a normal area. A tuning fork heated in water of 
40 degrees Celsius and cooled in water of 15 degrees Celsius, was used for the 
thermal allodynia testing. All stimuli were applied first to an adjacent or contra lateral 
non-painful area and then to the painful area. Patients were asked to say whether 
the stimulus felt "the same", "less intense" or "more intense". For vibration sense, a 
128 Hz tuning fork was used. The stimulus was first applied to a joint in a non-painful 
area, such as the wrist. It was then applied to joints in the area of pain, such as the 
knee, medial malleolus and IP joint of the big toe. Vibration sense was recorded as 
"present" or "decreased or absent". 
Motor aspects of this examination included distal muscle strength and the deep 
tendon reflexes. Where the lower limbs were painful, the strength of the big toe and 
ankle dorsiflexion was compared to finger spread and recorded as either "the same" 
or "weaker". Depending on the area of pain, the ankle or supinator reflex was 
compared to a more proximal reflex and recorded as "the same" or "absent or 
decreased". In cases where the pain was situated in an area other than a limb, 
vibration sense, muscle strength and the deep tendon reflexes were not tested. 
• A section regarding temporal aspects of the neuropathic pain and whether any 
analgesia had been prescribed in the month prior to the study. 
• Intensity of pain of predominantly neuropathic origin: 
Numerical rating scales were used to rate the intensity of worst and average pain. 
Patients were asked to select a number from 0-10 to indicate the intensity of their 
pain during the past week. Zero was labeled as "no pain" and 10 was labeled as 
"unbearable pain". 
• Impact of pain of predominantly neuropathic origin: 
Patients were asked to rate how much the pain interfered with their walking, working 
ability, sleep, relations with other people, mood and enjoyment of life, during the past 
week. They were asked to select a number on an 11-point numerical rating scale to 
indicate the degree to which the pain interferes with each aspect of their daily 












The questions regarding intensity and impact of pain were adapted from the Brief Pain 
Inventory. This instrument has been validated in several studies of various kinds of pain, 
including diabetic peripheral neuropathy and pain in AIDS patients (Zelman et ai, 2005; 
Poundja et ai, 2007; Keller et ai, 2004). 
Analysis of data: 
Data was analysed using SPSS for Windows statistical software. 
Descriptive statistics were produced to examine the study sample, the prevalence of POPNO 
(DN4 score of 4 or more), the severity of the POPNO and pain-related interference. Means ± 
standard deviations were used for continuous variables and frequency distributions for 
categorical variables. 
Factors associated with the presence of POPNO and the severity of POP NO were identified 
using Chi squared tests of Independence. 
Statistically significant differences between the severity of POPNO and interference items 
were evaluated by means of non-parametric tests using the Kruskal Wallis statistics. The 
Pearson's Correlation Coefficient was also calculated to identify significant linear 
relationships between variables. 
Statistical significance was evaluated at the 95% level of confidence. 
The analysis focused on the following aspects: 
1. The prevalence of pain that is predominantly neuropathic pain in origin. 
3 Factors associated with the occurrence of POPNO. 
4. The severity of POPNO. 
5. The perceived interference of POPNO on certain aspects of daily functioning. 
6. The correlation between the severity of POPNO and pain-related interference with 
daily functioning. 
7. Frequently occurring symptoms and signs of POPNO, as demonstrated by the DN4 












All possible candidates for the study received information by means of the study information 
sheet and by a research assistant. They were assured that participation in the study was 
entirely voluntary and that if they chose not to participate or to withdraw from the study, they 
would still receive standard care as offered at the clinic. 
Care was taken to ensure that participation in the research study did not negatively influence 
the patients' management at the ARV Clinic. No clinical or counselling session was delayed 
in favour of the research interview. Certain patients, however, needed to stay at the clinic a 
while longer following their clinical sessions, to be able to participate in the study. 
All information obtained from the study participants was treated as confidential and no patient 
names appeared on the study questionnaires. Any publication resulting from this study will 
be presented in such a fashion that patients remain unidentifiable. 
In cases where significant pain or other problems were identified during the data collection 
procedure, a referral to the doctor on duty at the HIV clinic was offered to the patient. Several 
patients, with acute or severe problems, benefited from the direct and fast referrals they 
received in this manner. 
This study received full approval from the Research and Ethics Committees of the University 


















































More than half of the patients had a CD4 count of more than 100 cells/mm3. The average 
CD4 cell count was significantly lower for males than females (P<0.001). 
Most patients (54.6%), had high viral loads of 100 000 copies/ml and over. In male patients, 
these were significantly higher than in female patients (P=0.028). 
Twenty one percent of the patients had used treatment for tuberculosis in the past two 
weeks. By far the majority of these were male, with those using treatment for tuberculosis 
comprising 40.6% of the male sample, as compared to only 13.6% of the female sample 
(P<0.001). 
Pain of any type within the total patient sample 
The prevalence of frequent or persistent pain of any type within the whole sample was 62.1 % 
(220 patients). Male patients experienced significantly more pain (P=0.011), with 72.9% 
having pain, compared to 58.1 % of female patients. 
Figure 1 shows the prevalence of frequent or persistent pain, of any type, for different levels 
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Figure 1. The association between the presence of frequent or persistent pain of any 
type and CD4 count level 
There is a trend towards an increased prevalence of pain as the CD4 cell count becomes 











Figure 2 shows the anatomical distribution of frequent or persistent pain, of any type. 
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Figure 2. Anatomical distribution of frequent or persistent pain, of any type (n=220) 
The commonest sites of pain were the feet (34.1%), the abdomen (27.3%), the back and 
neck (22.3%), the chest (20.9%) and joints of the lower limb (14 .1%), 
Prevalence of pain of predominantly neuropathic origin 
All of the 220 patients (62.1 %) with frequent or persistent pain were tested for the presence 
of pain of predominantly neuropathic origin (POP NO), using the DN4 instrument. These 
results are shown in Table III. The frequencies for patients without any pain are included in 











Table III. Presence of pain of predominantly neuropathic origin as indicated by the 
DN4 score (n=354) 
DN4 total score n (%) 
No pain (DN4 not done) 134 (37.9%) 
DN4 total score 0-3 146 (41 .2%) 
DN4 total score 4-10 74 (20.9%) 
Total 354 (100%) 
This shows that 74 patients (20.9%) in the total sample have pain that is predominantly 
neuropathic in origin, as indicated by a DN4 score of 4-1 0 (95% CI= 16.8% to 25.2%). Of the 
220 patients in the subsample that had pain, 33.6% had POPNO. 
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Chi-Squared analysis was done to assess the impact of the following variables on the 
prevalence of pain of predominantly neuropathic origin: gender, age, CD4 count, viral load 
and the use of treatment for tuberculosis. The results of this are displayed in table IV. 
A significantly higher percentage of male patients (31.3%), as compared to 17.1 % of the 
female group, had a score indicative of POPNO (P=O.003). 
There was a trend towards older patients having a higher prevalence of POPNO, however, 
the analysis did not demonstrate significant differences between age groups. 
Patients with lower CD4 cell counts (P=O.009) and those with higher viral load values 
(P=O.006) showed a significantly higher prevalence of POPNO. 
Those patients with a history of recent or current use of treatment for tuberculosis 































The DN4 instrument 
Figure 4 indicates how frequently each of the items (symptoms and signs) of the DN4 
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Figure 4. Frequency of each of the DN4 items, in patients identified as having POPNO 
(n=74) 
The most frequent symptoms encountered were burning pain in 61 patients (82.4%) and 
abnormal pain-related symptoms, such as pins and needles, in 58 patients (78.4%), itching in 
51 patients (68.9%) and numbness in 50 patients (67.6%). 
As evident from the above figure, the examination items occurred less frequently than most 











Characteristics of pain of predominantly neuropathic origin 
Anatomical location of POPNO: 
The location of the pain in patients identified as having POPNO is shown in Figure 5. 





Figure 5. The location of pain in patients with POPNO 
By far the majority of patients (62 out of 74) had pain in their feet only or both feet and legs. 
Two of the patients (not indicated on the chart) had POPNO in two different sites. 
Temporal aspects of POPNO: 
In most patients (52.7%), the pain had been present for months, while in 18.9%, it had been 
there for several years. 85.1 % reported the pain to be present both day and night, of whom 
66.7% found it worse at night. 
Analgesic medication prescribed: 
Only 29.7% of the patients with POPNO could remember having analgesic medication being 
prescribed for the pain, by their doctor or clinic, in the past month. It was beyond the scope of 
this study to determine how many of the patients had actually consulted a doctor or clinic in 












In order to determine some of the clinical characteristics of pain of predominantly neuropathic 
origin in this population, a focused neurological examination was done on all the patients 
identified as having POPNO (74 patients). 
Figure 6 shows the frequency of an abnormal examination result for each aspect of the 
focused neurological examination. Items, such as vibration sense, distal reflexes and muscle 
strength were not applicable to all POPNO patients. In these cases, the frequency was 
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Figure 6. Frequency of abnormal examination for each aspect of the focused 
neurological examination 
*80th increased and decreased tactile and pinprick sense were regarded as abnormal. The 
clustered bars indicate the frequencies of each of these. 
The most frequent abnormal examination findings were abnormal pinprick sense in 54 
patients (73%), most of whom demonstrated a decreased pinprick sense (50.0%). Testing of 
tactile sense revealed similar results, with 51 patients (68.9%) showing abnormalities, of 
whom most showed a decreased tactile sense (47.3%). Other commonly-occurring 
neurological abnormalities were decreased or absent vibration sense (62.1 % of patients), 











In order to further characterise patients with pain of predominantly neuropathic pain, the 
number of abnormal neurological examination items per patient was analysed. The focused 
neurological examination consisted of nine items. Therefore, anyone patient could have a 
maximum of nine abnormalities. These results are displayed in figure 7. 
n=74 
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Figure 7. Number of abnormal neurological examination items per patient with 
POPNO 
Using the focused neurological examination, six of the 74 patients (8.1%) displayed no 
neurological abnormalities. At the opposite end of the spectrum, 7 patients (9.5%) had 
abnormal findings for seven of the nine examination items. These results show that most, but 











Intensity of pain of predominantly neuropathic origin 
One of the objectives of the study was to determine the perceived intensity of the pain of 
predominantly neuropathic origin. Each patient identified as having POPNO was asked to 
rate his/her worst and average pain, during the past week, on a numerical rating scale. "0" on 
the scale was labelled as "no pain" and "10" was "unbearable pain". These results are 
displayed in table V. 
Table V. Intensity rating of pain of predominantly neuropathic origin 
n (%) 
Mild pain Moderate Severe Mean pain SO 
(1-3) pain (4-7) pain (8-10) score 
Worst pain 9 (12.2%) 34 (45.9%) 31 (41.9%) 6.31 (2.57) 
Average pain 54 (73.0%) 16 (21.6%) 4 (5.4%) 2.41 (1.79) 
These results show that when the pain is at its worst, a large percentage (41.9%) 
experienced it as severe. It was only in a few of the respondents (12.2%) that the pain was 
never experienced as more than mild . 
Chi-squared analysis was done to assess whether the variables of gender, age, CD4 count, 
viral load and the use of treatment for tuberculosis had any impact on the severity of the pain 
at its worst. The results are shown in table VI. 
From this table, it can be seen that none of these variables had a significant influence on the 
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Pain at its worst 
Moderate Severe p- value 
(4-7) (8-10) (Chi-
Squared) 
45.9% 41 .9% 
50.0% 36.7% 
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56.7% 26.7% 




























TABLE VII. Impact of pain of predominantly neuropathic origin on aspects of daily 
living (n=74) 
Pain Interference Rating n or mean %orSD 
Walking 
Mild (0-3) 38 (51.4%) 
Moderate (4-7) 18 (24.3%) 
Severe (8-10) 13 (17.6%) 
Unspecified 5 (6.8%) 
Mean score 3.59 (3 .34) 
Ability to work 
Mild (0-3) 34 (45.9%) 
Moderate (4-7) 17 (23.0%) 
Severe (8-10) 19 (25.7%) 
Unspecified 4 (5.4%) 
Mean score 4 .01 (3.59) 
Sleeping 
Mild (0-3) 41 (55.4%) 
Moderate (4-7) 16 (21.6%) 
Severe (8-10) 17 (23.0%) 
Unspecified 0 
Mean score 3.61 (3.53) 
Mood 
Mild (0-3) 35 (47.3%) 
Moderate (4-7) 18 (24.3%) 
Severe (8-10) 20 (27.0%) 
Unspecified 1 (1.4%) 
Mean score 4.23 (3.45) 
Relations with other 
people 
Mild (0-3) 49 (66.2%) 
Moderate (4-7) 13 (17 .6%) 
Severe (8-10) 10 (13.5%) 
Unspecified 2 (2.7%) 
Mean 2.07 (3.08) 
Enjoyment of life 
Mild (0-3) 33 (44.6%) 
Moderate (4-7) 21 (28.4%) 
Severe (8-10) 19 (25.7%) 
Unspecified 1 (1.4%) 











Correlation between pain intensity and interference items 
The correlation between the severity of POPNO at its worst and interference with aspects of 
daily living was tested using the Kruskal Wallis Test and Pearson's correlation coefficient. 
These results are shown in Figure 8 and Table VII. 
Figure 8 shows a significant correlation between pain severity and the global or overall pain-
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Table VIII displays the correlation between worst pain severity and the mean pain-related 
interference score for the individual domains of daily living. 
Table VIII. Correlation between POPNO at its worst and individual interference items 
(n=74) 
Pain at its worst 
n Pearson correlation P-value 
coefficient 
Walking 69 0.565 <0.001 
Ability to work 70 0.558 <0.001 
Sleep 74 0.518 <0.001 
Relations with other people 72 0.303 0.010 
Mood 73 0.456 <0.001 
Enjoyment of life 73 0.555 <0.001 
A significant positive correlation exists between worst pain severity and the overall pain-













This study presents evidence of the prevalence, characteristics and impact of pain of 
predominantly neuropathic origin, in patients with AIDS, before the use of ARV therapy. 
Demographics of sample 
The majority of the study sample was female (over 70%) and under 40 years (66.6%). The 
higher percentage of females in the sample, corresponds with the usual gender ratio of 
patients attending this clinic, where two thirds of the patients are female. Patients in this 
sample had a mean age of 36.3 years, which is similar to that of a study of AIDS patients in 
Kenya, where the mean sample age was 33.0 years (Mbuya et ai, 1996). The mean age of 
the male group of patients was 5 years older than that of the female group. This is consistent 
with a 2005 national study within the general population in South Africa, where the 
prevalence of HIV infection in females peaked in the 20-29 year-old age group, while in 
males this prevalence peaked 10 years later, in the 30-39 year old age group (Rehle et ai, 
2007). 
The average CD4 cell count was 111 cells/mm3 . The male group was characterised by a 
significantly lower mean CD4 cell count, a significantly higher viral load and a significantly 
higher prevalence of the use of treatment for tuberculosis. This seems to indicate that, in 
general, the male patients, referred to this ARV clinic, have more advanced AIDS than the 
average female patient. Several factors could account for this. It might be that pregnancy has 
a positive spin-off for the female patients. Pregnant patients are routinely offered HIV testing 
during visits to antenatal care facilities. This might lead to earlier diagnosis of HIV infection 
within the female sector of the community, which is usually followed by timely referral for 
ARV therapy. It is also possible that many HIV-infected males in this community delay 
seeking health care from public health facilities, until their illness becomes more 
symptomatic. Furthermore, Prins et ai, 1999, have shown that women seroconvert for HIV, 











Prevalence of pain 
Of the total sample, 62.1 % experienced frequent or persistent pain within the preceding two 
weeks. This figure is similar to the studies of Larue et ai, 1997; Breitbart et ai, 1996a; Singer 
et ai, 1993 and Schofferman et ai, 1990, where 50% -80% of AIDS patients had pain. 
Patients with frequent or persistent pain were more likely to be male (72.9% males with pain 
vs. 58.1 % females with pain; P=0.011) and tended to have a lower mean CD4 count, 
although a significant difference in pain prevalence between different CD4 cell count levels, 
was not demonstrated (P=0.216). Since the male sample appeared to have more advanced 
disease, it is not unexpected that this group had a higher prevalence of pain. 
The most frequent locations of pain were the feet (34.1 % of patients with pain), the abdomen 
(27.3%), the back and neck (22.3%), and the chest (20.9%). This bears some resemblance 
to a USA study by Schofferman et ai, 1990, of pain in far advanced AIDS, where peripheral 
neuropathy, abdominal pain, headaches and skin conditions (such as Kaposi's sarcoma and 
pressure sores) were found to be the four commonest causes of pain. A further study by 
Hewitt et ai, 1997, from the USA, also found headache and peripheral neuropathy to be 
among the top four causes of pain in AIDS patients. These USA studies focused on pain 
aetiologies, rather than anatomical locations of pain and are therefore not directly 
comparable to the present study. 
The high percentage of patients with pain in the feet, most likely relates to the high 
prevalence of various painful peripheral neuropathies in AIDS patients (affecting 
approximately one third of patients with CD4 cell counts below 200 cells/mm3 ) (Wilson et ai, 
2002). A previous study of pain in ambulatory HIV-infected men, by Singer et ai, 1993, found 
that of the patients with pain, 59% were related to peripheral neuropathy. Multiple 
pathologies may result in pain in the abdomen in patients with AIDS, including cryptosporidial 
and other infective diarrhoeas, mycobacterium avium-intracellulare infection, lymphoma, 
Kaposi's sarcoma, pancreatitis and acalculous cholecystitis (O'Neill et ai, 1993). 
Prevalence of Pain of Predominantly Neuropathic Origin 
The prevalence of POPI\IO was based on achieving a score of 4 or more (range 0-10), using 
a relatively new neuropathic pain diagnostic questionnaire, the DN4 (Bouhassira et ai, 2005). 
This instrument has been preliminarily validated and has a sensitivity of 82.9% and specificity 
of 89.9%, for neuropathic pain (Jensen, 2005). All of the 220 patients with frequent or 
persistent pain, completed this researcher-administered questionnaire and examination. 
Using this method, 20.9% of the patients in the total sample were identified as having 











This study's POP NO prevalence of 20.9%, is somewhat lower than that found in previous 
studies. Two studies with patients with AIDS, done in the USA, found the prevalence of 
symptomatic DSP to be 35% (Schiffito et ai, 2002 & So et ai, 1988). One of these studies 
involved hospitalised patients, which could explain the higher prevalence. The present 
study's prevalence of POPNO concurred with a study of Nakasujja et ai, 2005, done in 
Uganda, where the prevalence of a symptomatic peripheral neuropathy was found to be 
20%. It should be noted that none of these studies are directly comparable with the present 
study, which examined neuropathic pain in general, as opposed to symptomatic peripheral 
neuropathy only. In Breitbart et ai, 1996a's study of ambulatory AIDS patients in New York, 
46% of the subset of patients with pain were identified as having neuropathic pain. The 
present study found that only 33.6% of the subset of patients with pain had POPNO. It is 
likely that many of the patients in the New York study were already using ARV's and a toxic 
neuropathy secondary to ARV's may have played a role in the higher frequency of 
neuropathic pain . Antiretroviral agents and drugs targeting opportunistic infections and 
malignancies are thought to cause up to 30% of neuropathic pain syndromes in patients with 
H/V infection (Stephenson, 1996). 
In a study of underestimation and under treatment of pain in H/V disease, by Larue et ai, 
1997, it was found that pain severity was better assessed and possibly treated, by clinicians, 
when the source of the pain could be identified. While it was not within the scope of this 
study to identify the aetiologies of the neuropathic pain, the location of pain may be able to 
give some indications of these. Eighty-four percent (62 out of 74 patients) experienced the 
pain in their feet or both feet and legs. Predominantly neuropathic pain, located in the feet in 
patients with AIDS, is highly likely to be as a result of various AIDS-related or medication-
related peripheral neuropathies. Therefore, more than 80% of POPNO in this study is 
probably related to peripheral neuropathy. The second most likely site of POPNO in this 
study was the chest. It can be speculated that post-herpetic neuralgia might frequently have 
been the cause of the POPNO in the chest. Other causes of neuropathic pain in AIDS 
patients, that might have played a role, are those related to nerve compression by 
malignancies such as Kaposi's sarcoma and lymphoma (Katz, 2000) and post-stroke pain 
(Dworkin et ai , 2003). In the present study, patients were not asked specifically about the 
presence of diabetes mellitus or the use of alcohol. It is possible that peripheral neuropathy, 
secondary to diabetes or nutritional deficiency, could have contributed to neuropathic pain in 
the lower limbs (Dworkin et ai, 2003). 
The analysis of the association between the presence of POPNO in this sample and 
demographic and disease-related characteristics, revealed certain definite associations. A 











lower CD4 cell count (P=0.009), those with a higher viral load (P=0.006) and those using 
treatment for tuberculosis (P<0.001). This confirms the findings of other studies, where lower 
CD4 cell counts (Tagliati et ai, 1999 & Hewitt et ai, 1997), higher viral loads (Brinley et ai, 
2001) and male gender (Tagliati et ai, 1999) were significantly associated with a higher 
prevalence of polyneuropathy. Simpson et ai, 2002, found a significant, albeit weak 
association between plasma viral load and the severity of peripheral neuropathy. Previous 
research also found Caucasian race and older age to be significantly associated with an 
increased prevalence of polyneuropathy (Tagliati et ai, 1999). The present study did not find 
a significant difference in prevalence amongst different age groups. Race was not included in 
the questionnaire. The association between the use of certain anti-tuberculous drugs, such 
as II\lH and painful peripheral neuropathy, is well known (Wilson et ai, 2002). It is therefore 
not unexpected that use of tuberculosis treatment was associated with a higher pain 
prevalence of POPNO. 
Intensity of pain of predominantly neuropathic origin 
Several studies indicated that pain management in HIV patients is inadequate (Stephenson, 
1996; Larue et ai, 1997; Breitbart et ai, 1996b; Breitbart et ai, 1998). One of the reasons cited 
for this was the underestimation of the severity of pain, by medical practitioners (Larue et ai, 
1997). In a study of Larue et ai, 1997, it was found that clinicians had underestimated pain 
severity in 52% of HIV patients reporting pain. Of note is, that it was pain in the moderate and 
severe range that was most likely to be underestimated. One of the objectives of the present 
study was to increase awareness amongst clinicians, of the severity and impact of 
neuropathic pain in AIDS patients. This could potentially lead to improved management of 
this pain. For this reason, all patients with POPNO were asked to rate how they experience 
this pain, at its worst and on average. 
A large percentage of patients (41.9%), experienced their "worst pain" as severe (rating of 8-
10), while only 12.2% found that their POPNO was never more than a mild pain (rating of 1-
3). The mean score for "worst pain" was 6.31 (±2.57) and the median 5.5. 
Pain studies on HIV patients by Larue et ai, 1997 & Cleeland et ai, 1994, regarded "worst 
pain", that was rated as 5 or above, as substantial pain, because studies prior to these have 
shown that patients with a worst pain rating of ~ 5, on a 0-10 scale, report disproportionately 
more functional impairment. 
In the present study, 59 out of 74 (79.7%) POPNO patients rated their worst pain as 5 or 
higher and could therefore be regarded as having substantial pain. This is disturbing, 
considering the fact that fewer than a third of patients (29.7%), could remember having an 











however, beyond the scope of this study to determine what percentage of these patients had 
actually consulted a health care practitioner in the previous month. The problem of the under-
treatment of pain related to HIV and AIDS, has been noted in several studies. Breitbart et ai, 
1996b found that 85% of ambulatory AIDS patients in their sample, received inadequate 
analgesia (based on WHO guidelines for analgesic therapy). Of the patients whose pain-
severity warranted opioid analgesics, only 7% received these Research done by Breitbart et 
ai, 1999 highlighted several barriers to adequate pain management in patients with AIDS and 
other chronic diseases, some relating to patient factors and others to the clinician or the 
health care system. One reason is under-diagnosis of painful conditions or under-estimation 
of the severity thereof. This may be the result of doctors focusing most of their attention on 
antiretroviral treatment and reversing opportunistic infections. In the busy primary care 
setting, little time is left for the management of symptoms. Both physicians and patients may 
have fears regarding the development of tolerance to the analgesia, as well as the addiction 
potential and side effects of opioid medication. 
A French study of general pain in HIV patients by Larue et ai, 1997, found that 16% of their 
out-patients and 51 % of their in-patients had substantial pain (worst pain level <!5). Cleeland 
et ai, 1994 found that sixty two percent of patients with metastatic cancer, in the USA, scored 
their worst pain as 5 or higher, using the BPI. The substantial pain percentage in the present 
study was higher than in both of these studies, which suggests high levels of pain severity 
with neuropathic pain in AIDS patients. This is consistent with a United Kingdom chronic 
POPNO study within the general population by Smith et ai, 2007, where the group with 
chronic POP NO reported higher pain severity and more pain-related interference than the 
non-POP NO group with chronic pain . Another study, however, of frequent or persistent pain 
of any type, in ambulatory AIDS patients in New York City, found that 48.7% of their sample 
reported their pain as severe (rating 8-10), with a mean worst pain intensity of 7.2 (2 .1) 
(Breitbart et ai , 1998). This suggests a similar pain severity in patients with POPNO or 
general HIV-related pain . These differences may relate to the different populations tested . 
More evidence is required in this regard . 
The "worst pain" scores in the present study are similar to those found in other neuropathic 
pain studies. Torrance et ai, 2006 reported a median pain severity score of 7.0 in the chronic 
POPNO study, within the general population, in the United Kingdom, while the mean worst 
pain severity score in studies of post-herpetic neuralgia and several studies of diabetic 
peripheral neuropathy were 6.0 (±2.4), 5.6 (±2.8) and 6.9 (±2.4) respectively (Galer et ai, 
2000; Oster et ai, 2005; Gore et ai, 2005). Other neuropathic pain studies used a pain 











therefore not be used for comparison with the present study (Galer et ai, 2000 & McDermott 
et ai, 2006). 
For "average pain", most patients (73.0%) experienced the pain as mild. Many of the 
respondents found the concept of average pain difficult to understand and it is likely that 
many of the "average pain" ratings, were in actual fact ratings of pain at its least. Even then , 
over 25% of patients experienced their average POPNO as moderate or severe. Twelve out 
of 74 patients (16.2%) indicated a score of 5 or higher for average pain . 
Impact of POPNO 
POP NO patients were asked to rate the degree to which their pain of predominantly 
neuropathic origin, affected six aspects of their daily living. The greatest degree of pain-
related interference was reported for "enjoyment of life" (mean rating 4.25 ±3.30), "mood" 
(mean rating 4.23 ±3.45) and "ability to work" (mean rating 4.01 ±3.59). At least 25% of the 
POPNO patients experienced severe pain-related interference for these three aspects of 
functioning . In addition, almost one quarter of patients found that their sleep was severely 
affected by the pain (mean rating 3.61 ±3.53). 
In a study by Oster et ai, 2005 of patients with post-herpetic neuralgia, enjoyment of life, 
mood and sleep were most affected, with mean interference ratings of 4.5 (±3.1), 4.3 (±2.9) 
and 3.8 (±2.9) respectively. The interference ratings in this study are strikingly similar to 
those of the present study. Interference with sleep has been found to be among the most 
common pain-related problems reported by patients with neuropathic pain (Jensen et ai, 
2007). 
When using the BPI, the seven pain interference subscales may be averaged to provide an 
overall measure of pain-related functional interference (Breitbart et ai, 1996b). Studies of 
neuropathic pain in general, as well as trigeminal neuralgia and diabetic peripheral 
neuropathy, found overall pain-related interference scores of 4.5, 5.9 and >5 (range 0-10), 
respectively (Galer at ai, 2000; McDermott et ai, 2006; Tolle et ai, 2006). Several USA 
studies of general pain in patients with HIV, found overall pain interference scores of 4.38 
and 6.1 (range 0-10) (Breitbart et ai, 1996b & Breitbart et ai, 1998). The overall pain-related 
interference for the six items, adapted from the BPI, in the present study, was 3.6 (range 0-
10). 
The fact that patients with POPNO, in the present study, reported a lower overall pain-related 
interference than HIV patients with general pain, was unexpected. Limited evidence suggests 
that patients with chronic neuropathic pain have poorer scores for pain-interference items 











scores in the present study could be due to the sampling in this study. It is possible that 
some of the most ill and disabled patients were unable to get to the HIV clinic, since most of 
the community served by this hospital are dependent on public transport. A further 
contributing factor could be cultural differences in how patients perceive and express pain-
related interference. 
The six domains of daily functioning may be classified into physical functioning (walking, 
sleeping), emotional functioning (mood, enjoyment of life) and role and social functioning 
(ability to work, relations with other people). A similar classification was used in a review of 
Jensen et ai, 2007, which examined the impact of neuropathic pain on health-related quality 
of life. 
The severity of pain of predominantly neuropathic origin was significantly associated with 
greater interference in each of the domains of daily functioning (P<0.001 for all, except 
relations with others) . Relations with other people, however, correlated the least with pain 
severity (P=0.01). This confirms the findings of several previous studies, where increasing 
pain intensity was significantly associated with greater impairment in functional ability in 
several domains of daily living (Breitbart et ai, 1996a & Gore et ai, 2005) . In a review of the 
impact of neuropathic pain on quality of life, by Jensen et ai, 2007, patients reported less 
impact on social relationships than on other domains of functioning. It is possible that these 
patients, who are generally more dependent on other people due to their respective 
diseases, avoid contemplating the possibility that their pain might negatively influence these 
valuable relationships. Alternatively, the disability caused by the pain , may, in many cases, 
evoke greater caring by other people, leading to improved relationships between the patient 
and their social support persons. 
Symptoms and signs of POPNO 
Burning pain (82%), pins and needles paresthesia (78%), itching (69%) and numbness 
(68%) were the commonest symptoms experienced by patients identified, by the D1'J4 , as 
having POPNO. 
A Swedish study by Martin et ai, 2003 of peripheral neuropathy in HIV-infected patients had 
similar findings, with numbness (75%), pins and needles (70%) and burning pain (65%) 
being the commonest symptoms in patients with painful peripheral neuropathy. 
These findings concur with much of the literature, where burning pain, pins and needles 
paresthesia and numbness are the commonest symptoms of peripheral neuropathy 











A focused neurological examination revealed that the majority of POPNO patients had a 
minimum of three neurological abnormalities. However, 8.1 % of POPNO patients had no 
objective neurological abnormality. This indicates that, while most patients with neuropathic 
pain can be expected to have some evidence of this on neurological examination, a small 
percentage have symptoms, but no signs of this condition. This is confirmed by the work of 
Backonja et ai, 1998, who state that, "the lack of physical findings does not rule out the 
presence of neuropathic pain". 
Abnormal pinprick sensation (73.0%) and tactile sensation (68.9%), both in which the 
sensation was more frequently decreased, were the commonest findings on the neurological 
examination. This was followed by decreased or absent vibration sense in 62.1 % of POPNO 
patients. Findings of other studies of peripheral neuropathy or DSP, demonstrated impaired 
tactile and pinprick sensation in between 71 % and 100% of patients (Tagliati et ai, 1999 & 
Martin et ai, 2003). Other researchers, including those from a Kenyan study by Mbuya et ai, 
1996, found vibration sense diminished or absent in 60-65% of cases of peripheral 
neuropathy. One of these studies demonstrated reduced or absent ankle reflexes in 66% 
(Tagliati et ai, 1999). The present study found diminished ankle reflexes in fewer cases 
(39.4%). This might relate to technical difficulty in eliciting this sign, because patients with 
substantial pain found the testing for distal reflexes very uncomfortable. 
Clinical descriptions of HIV related peripheral neuropathy in the literature frequently allude to 
evoked pain, such as when touching bed sheets, wearing shoes and walking (Polydefkis, 
2002). It would therefore be expected that allodynia would be a common finding in these 
patients with POPNO, largely due to peripheral neuropathy. In this study, while static 
mechanical allodynia (evoked by a pressure stimulus) occurred quite frequently, in 47.3%, 
dynamic mechanical allodynia (evoked by a moving stimulus) was present in only 18.9%. 
This concurs with a French study of HIV related peripheral neuropathy by Bouhassira et ai, 
1999, where static mechanical allodynia was common, while dynamic allodynia was elicited 
in only 20%. It has been suggested in the literature that the static and dynamic sub-types of 
mechanical allodynia involve different neural mechanisms (small versus large afferent fibres 
and peripheral versus central sensitisation, respectively) (Tagliati et ai, 1999). This may have 











Strengths and limitations of the study 
The demographic characteristics of the sample were compared with those of the general 
patients attending the Kalafong HIV clinic. Their similarity indicated that there were unlikely to 
be any important sampling biases amongst the patients who attended the clinic. 
Representation in this sample was limited to patients with AIDS, who were both willing and 
able to attend this particular public health facility for ARV therapy. It therefore excluded those 
who do not wish to use ARV therapy, or who were unable to attend the facility due to 
physical disabilities and/or socio-economic factors. This could have resulted in a 
disproportionate number of patients who are most impacted upon by AIDS, being excluded 
from the sample. Furthermore, the sample was restricted to patients who are reliant on public 
health care and those patients not yet using antiretroviral therapy. Further research should 
be done, involving more varied populations and patients on ARV therapy, to determine the 
influence of antiretroviral therapy on the prevalence of neuropathic pain in patients with 
AIDS. The widely-used NRTl's, such as didanosine and stavudine are well known to 
sometimes cause a painful sensory neuropathy (Brinley et ai, 2001). 
Certain participants found it difficult to distinguish between functional interference by the 
POPNO and that due to other pain or physical impairments. In these cases, scoring of 
certain of the interference items was omitted. 
A further limitation could be that the study relied, to a large extent, on self-report data, at a 
single point in time. It is, however, unlikely that patients would have purposefully exaggerated 
their pain or pain-related interference, since no additional treatment was offered in 
connection with the study, other than expediting a referral to the HIV clinic doctor in the case 
of acute problems. Furthermore, the researcher-administered questionnaire enabled 
respondents to motivate their replies, indicating their understanding of the instruction and 











Summary of discussion 
• A prevalence of 20.9% was found for POPNO, in patients with AIDS, in this study. 
• POPNO was significantly more likely in male patients, patients with a lower CD4 cell 
count and a higher viral load and those using treatment for tuberculosis. 
• The majority of POPNO patients (79.7%) experienced substantial pain (worst pain 
severity rating ~5 out of 10) and even average pain was reported as moderate or 
severe in 25% of patients. 
• POPNO severity in the present study concurred with that in other studies of 
neuropathic pain syndromes. 
• There is limited evidence, from this and other studies, that POP NO is experienced as 
more severe than other AIDS-related pain and even cancer pain . 
• Aspects of daily living most impacted upon by POPNO are e joyment of life, mood 
and the ability to work. 
• Pain-related interference is significantly correlated with the severity of POPNO for all 
aspects of daily living. 
• While the severity of POPNO in the present study was as severe as that in other 
neuropathic pain or POPNO studies, the overall pain-related interference score was 
lower than that in other neuropathic pain studies. 
• This and other studies of neuropathic pain, indicate that burning pain, pins and 
needles and numbness are generally the most frequent symptoms of neuropathic 
pain. 
• While most patients with POPNO exhibit several neurological abnormalities in the 
area of their pain, a small group of POPNO patients show no objective neurological 
findings. 
• Abnormalities in tactile and pinprick sensation and vibration sense are the most 












CONCLUSIONS AND RECOMMENDATIONS 
This study demonstrates a substantial patient burden, relating to pain of predominantly 
neuropathic origin, in patients with AIDS, prior to the use of ARV therapy. 
The presence, but not the severity, of the pain of predominantly neuropathic origin, is 
associated with male patients, lower CD4 cell count levels, higher viral load levels and 
patients using treatment for tuberculosis. 
In the light of this, clinicians treating patients with AIDS should actively screen for symptoms 
of neuropathic pain. Typical symptoms of neuropathic pain, as found in this study, include 
burning pain, pins and needles paresthesia, numbness, or itching in the area of pain. A brief 
neurological examination may help to verify the diagnosis, however, positive neurological 
signs may not be found in every case of neuropathic pain. Clinicians are often faced with 
limited consultation time. In this situation, the neurological examination may be restricted to 
testing for impairment of tactile or pinprick sense and vibration sense, since these aspects 
are the most likely to yield positive results . 
The majority of patients with neuropathic pain, in this study, experienced substantial pain 
(worst pain severity ~ 5 out of 10). This substantial pain not only leads to significant patient 
suffering, but also affects their quality of life, in particular, their mood, enjoyment of life and 
ability to work. A strong correlation between the severity of the pain and interference with 
aspects of daily living was demonstrated. 
The results of this study indicate the need for meticulous pain assessment and management 
in patients with AIDS, which in turn, should lead to improved quality of life for patients and 
keeping them economically active. In this regard, clinicians need to be optimally informed 
regarding the current guidelines for the management of neuropathic pain. This can be 
achieved by making short seminars or training courses on pain available to doctors. These 
training sessions should cover subjects such as the identification, assessment and 
appropriate management of neuropathic pain. The results of this study will also be submitted 
for publication, with the objective of informing clinicians about neuropathic pain in patients 
with AIDS. 
Unlike nociceptive pain, neuropathic pain requires a different approach, with particular 
emphasis on adjuvant drugs, in addition to non-opioid and opioid analgesics. The 
effectiveness of tricyclic antidepressants (TCA's), anticonvulsants, in particular the 02-<5 
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Patient Information Document 
Research study of physical problems in patients requiring ARVs 
Dear SirlMadam 
1. Dr Sonia Hitchcock is a family physician who works in the Kalafong Family Medicine 
Clinic and the Kalafong Immunology Clinic (ARV Clinic). She is presently doing 
research as part of a master's degree in palliative medicine. You are invited to be part 
of this research study. 
2. Nature and purpose of the study: 
This research involves certain physical problems in patients requiring antiretroviral 
medication (ARV's). It is anticipated that by knowing more about these physical 
problems, doctors will be able to diagnose and treat these problems more effectively. 
3. Procedures to be followed: 
This study involves answering a standard set of questions regarding certain of your 
physical problems. Depending on your physical problem(s), you may have to have a 
short examination of the feeling (sensation) and movement of your limbs. The 
questioning and the examination will be done by the researcher (Dr Sonia Hitchcock), 
with the help of a translator, where necessary. It will take between 5 and 20 minutes. 
Your CD4 cell count which appears on your referral letter for this clinic, will be 
recorded. The result of one other blood test, your viral load, which is routinely tested 
before you start to use ARV medication, will be recorded later on. This will be 
obtained from you hospital file once the result is available. 
You will be asked, at the end of the interview/ examination, whether the problem that 
you indicated should be documented by the researcher in your hospital file, so that 
the Immunology Clinic doctor can attend to it. 
4. Risk and discomfort involved: 
The only discomfort involved is for certain participants whose skin sensation will be 











5. Voluntary participation: 
Participation in this study is entirely voluntary and your willingness to participate or 
not will have no influence on the treatment you receive in this clinic. 
6. Confidentiality: 
All information obtained from you for this study will be regarded as confidential. No 
patient's name will be used in any presentation or publication of the results of the 
research. 
7. Once the results of this research have been collected and analysed, it may be written 
up in the form of a scientific article and published in a scientific or medical journal. 
8. Information: 
If you have any questions concerning this study, please contact Dr Sonia Hitchcock at 
Tel: 0123186814 
Cell: 082 579 5057 
Should you be willing to take part in this research, please sign the consent form on the 












Authorisation to Participate in a Research Project 
Title of study: 
Research study of physical problems in patients requiring ARVs 
1. Nature and purpose of the study 
I understand that I am being asked to take part in a research study. The aim of the 
study is to evaluate certain physical problems in patients requiring an tiretro viral 
medication (ARV's). By doing so we hope to leam more about these physical 
problems, so that doctors will be able to diagnose and treat these problems more 
effectively. 
2. Explanation of procedures to be followed 
This study involves answering a standard set of questions regarding certain of your 
physical problems. Depending on your particular physical problem(s), you may have 
to have a short examination of the feeling (sensation) and movement of your limbs. 
The questioning and the examination will be done by the researcher (Dr Sonia 
Hitchcock), with the help of a translator, where necessary. It will take between 5 and 
20 minutes. 
Your CD4 cell count which appears on your referral letter for this clinic, will be 
recorded. 
You will be asked, at the end of the interview/ examination, whether the problem you 
indicated should be documented, by the researcher, in your hospital file, so that the 
HIV Clinic doctor can attend to it. 
3. Risk and discomfort involved 
The only discomfort involved is for certain participants where the feeling (sensation) 
in the skin will be tested using mild pinpricks. 
4. I understand that if I do not want to partake in this study, I will still receive 
standard treatment for my illness. 
5. Confidentiality 
All information obtained from you, for this study, will be regarded as confidential. 













If you have any questions conceming this study, please contact Dr Sonia Hitchcock at 
Tel: 0123186814 
Cell: 082 579 5057 
7. Consent to participate in this study 
I have read or had read to me, in a language that I understand, the above 
information, before signing this consent form. The content and meaning of the 
information was explained to me. I have been given the opportunity to ask questions 
and am satisfied that these have been answered satisfactorily. I understand that if I 
do not participate, it will not alter my management in any way. I hereby volunteer to 
take part in this study: 
Patient Date 












Verbal patient informed consent (where patients are unable to read or write) 
I, the undersigned, Dr __________ , have read and have explained fully 
to the patient, named and/or his/her relative, the patient 
information leaflet, which has indicated the nature and purpose of the research study, 
in which I have asked the patient to participate. The explanation I have given has 
mentioned both the possible risks and benefits of the study. The patient indicated that 
he/she understands that he/she will be free to withdraw from the study at any time, for 
any reason. 
I hereby certify that the patient has agreed to participate in this trial: 
Patient's name 
I nvestigator's name 
Investigator's signature 
Witness's name Date _____ _ 













SECTION A: QUESTIONNAIRE INFORMATION 
Questionnaire number: Irecord 
File number Ifile 
SECTION B: DEMOGRAPHIC INFORMATION OF PATIENT 
11. Gender: 1 
2 11 
12. Age: 12 
13. CD4 cell count: 13 
14. Viral load 14 
I 5. Have you used any treatment for Yes 1 
tuberculosis in the past two weeks? 
No 2 IS 
SECTION C: PAIN PREVALENCE 
6. During the past two weeks, have you Yes, I have a problem 
1 
experienced any pain that has troubled with pain 
you a lot? 
No, I do not have a 
2 












SECTION D: DISTRIBUTION AND TYPE OF PAIN 
7. In the diagram, please shade in the areas where you feel pain. Put an X on the area that 




Head- scalp 1 Abdomen 10 
Headache * 2 Perineal 11 
Face, eye,ear 3 Perianal 12 
Mouth * 4 Upper limb- joint * 13 
Neck 5 Upper limb- other 14 
Odynophagia * 6 Lower limb- joint * 15 
Chest 7 Lower limb- other 16 
8ack- spinal 8 Feet 17 











SECTION E: DN4 QUESTIONS 
9(a) Do any of your pains i) Burning 
feel like any of the following ii) Painful cold 
descriptions? 
iii) Electric shocks 
9(b) Do you feel any of the i) Tingling 




9(c) Examination: i) Hypoesthesia to touch (using 
cotton wool) 































iii) Dynamic allodynia (brushing 
1 0 




All positive answers ('Yes') score 1, while negative answers ('No') score O. 
A total score of 4 or more out of 10 indicates pain which is predominantly neuropathic in 
origin. 
The remainder of the questionnaire will be completed only by patients with a DN4 
score of 4 or more. 
Patients with more than one source of pain will be reminded that the questions that follow 












SECTION F: FOCUSED NEUROLOGICAL EXAMINATION 
All stimuli are to be applied first to an adjacent or contra lateral, non-painful area, and then to 
the painful area. 
10. Tactile sense (using a cotton wool Same 1 
swab) 
Less intense 2 
More intense 3 /9 
11. Pinprick sense (using a cocktail Same 1 
stick) 
Less intense 2 
More intense 3 /10 
12. Vibration sense*: Present 1 
Decreased or absent 2 /11 
Non-applicable 3 
* Using a 128Hz tuning fork applied to the base of the big toe and medial malleolus and 
lateral wrist. Where the lower limbs are painful, big toe and medial malleolus vibration sense 
is compared with vibration sense in the upper limbs and vice versa. 
13. Mechanical allodynia : Static* No 1 
Yes 2 /12 
* Using blunt pressure with a finger tip that does not provoke pain in the normal area . 
14. Mechanical allodynia : Dynamic* No 1 
Yes 2 /13 
* Using a cotton wool swab brushed across the skin. 
15. Thermal allodynia: Same 1 
(Using a tuning fork heated in water of 
Less intense 2 
40°C) 











16. Thermal allodynia: Same 1 
(using a tuning fork cooled in water of 
Less intense 2 
15°C) 
More intense 3 115 
17. Distal muscle strength* Normal 1 
Distal muscles of painful 
2 
area weaker 
Non-applicable 3 116 
* Where the lower limbs are painful, the strength of big toe and ankle dorsiflexion is 
compared with finger spread, and vice versa). 
18. Deep tendon reflexes Same 1 
Wrist or ankle reflex -!, 2 
Non-applicable 3 117 
.. 
* Assess for a diminished or absent ankle or supinator reflex as compared to the knee or 











SECTION G: TIMING OF THE PAIN 
19. Would you describe your pain as Continuous 1 
continuous or intermittent? 
Intermittent 2 118 
20. How long have you had this pain? Days 1 
Weeks 2 
Months 3 
Years 4 119 
21 (a) Was any medication prescribed for Yes 1 
your pain in the past month (by your 
doctor, clinic or hospital)? No 2 120a 
21(b) What medication? 
120b 
22(a) What time of the day do you Day only 1 
experience this pain? 
Night only 2 
Both day and night 3 121a 
22b) If both day and night: Worse in the day 1 
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SECTION H: IMPACT OF THE PAIN 
(Adapted from the Brief Pain Inventory ) 
24. Think about how the pain has interfered with your life during the past week. 
Using a scale of 0 to 10 where 0 is "does not interfere at all" and 10 is "interferes completely", 
please choose the number that best describes how much the pain has interfered with your: 
a) Walking ability: 
0--------1--------2--------3-------4--------5--------6-------7 --------8--------9--------10 /23a 
b) Ability to work (this includes housework and work outside the home): 
0--------1--------2--------3--------4--------5--------6------7 --------8--------9--------10 /23b 
c) Sleep: 
0--------1--------2--------3--------4--------5--------6-------7 --------8--------9--------10 /23c 
d) Relations with other people: 
0--------1--------2--------3--------4--------5--------6-------7 --------8--------9--------10 123d 
e) Mood (e.g. how much sadness, anger, frustration or worry is caused by the pain): 
0--------1--------2--------3--------4--------5--------6-------7 --------8--------9--------10 /23e 
f) Enjoyment of life: 
0--------1--------2--------3--------4--------5--------6-------7 --------8--------9--------10 123f 
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